ONO Pharmaceutical Selects Genedata Expressionist for Mass Spectrometry
Global leader in drug discovery advances targeted proteomics and metabolomics with extended use of Genedata Expressionist
February 7, 2013
Basel, Switzerland and Tokyo, Japan
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that ONO PHARMACEUTICAL CO., LTD. (ONO) extended its Genedata collaboration with a license of Genedata Expressionist® for Mass Spectrometry. ONO is a leading R&D-oriented international pharmaceutical company, which provides treatments for oncological and cardiovascular diseases. The Genedata Expressionist system, an enterprise and comprehensive platform for omics data management, will be used by ONO to further strengthen its targeted proteomics and metabolomics research.
“Our daily research demands accurate mass profiling analysis as well as powerful MRM capabilities for effective quantitative analysis,” noted Director of Tsukuba Research Institute at ONO. “Genedata Expressionist for Mass Spectrometry supports our proteomics and metabolomics research with a sophisticated data analysis platform that can process chromatograms ranging from 2MB to over 1GB. And, the system’s ability to integrate data from a variety of instruments is a valuable benefit to us. Finally, with Genedata Expressionist we can rely on superior algorithms that generate clinically relevant biomarkers supporting efficient research processes.”
Experimental designs of molecular profiling studies in the life sciences are continually growing in complexity and size. Genedata Expressionist analyzes and manages genomic, transcriptomic, proteomics, metabolomics, and epigenomic data from leading technologies including next-generation sequencing, high-density microarrays, RT-PCR, and other genomic tools. Additionally, Genedata Expressionist enables integrated analysis and management of all major mass spectrometry (MS) profiling applications including a comprehensive solution for proteomic, metabolomic, and lipidomic data from all major MS technologies.
With robust support of MRM data, the system’s innovative capabilities include:
- Data Visualization
- Background Subtraction
- Grid Alignment
- Peak Detection
“We are proud of our collaboration with ONO, one of the world’s leading pharmaceutical companies providing innovative drug therapies,” said Dr. Othmar Pfannes, CEO of Genedata. “With Genedata Expressionist and its support of innovative technologies such as MS and next-generation sequencing, we provide an integrative computational platform that supports customers such as ONO who are pioneering novel therapies. And, we are committed to continuous innovation by expanding the scope Genedata Expressionist applications in areas such as molecular diagnostics and personalized healthcare.”
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.